freePRnow.com Plans | Login    

Author Details
Market Research Future
www.marketresearchfuture.com/
sales@marketresearchfuture.com

Bookmark and Share
Carcinoid Tumor Market To Record An Exponential CAGR By 2023
Carcinoid Tumor Market Research Report, Site (Lung, Gastrointestinal), Diagnosis (Serology, Imaging, Biopsy), Treatment (Chemotherapy, Radiotherapy), End Users (Hospital & Clinics, Academic Institutes, Research Organization)

freePRnow.com, 3/26/2020 - Carcinoid Tumor Market Highlights

Carcinoid tumor is a type of the neuroendocrine tumor. The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs. However, it can also be developed in pancreas, testicles, and ovaries. The increasing prevalence of the carcinoid tumor is expected to drive the market growth. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the US are diagnosed with a carcinoid tumor in their lung. Moreover, growing geriatric population along with rising healthcare expenditure is likely to boost the market growth during the forecast period. However, lack of awareness, high treatment cost and related side effects may hamper the market growth during the forecast period.

Avail Free Sample Copy at [FURL]https://www.marketresearchfuture.com/sample_request/4813[/FURL]

Carcinoid Tumor Market Segmentation

The global carcinoid tumor market is segmented on the basis of site, diagnosis, treatment, and end users.

On the basis of the site, the market is segmented into gastrointestinal, lung, and others. Furthermore, the gastrointestinal segment is sub-segmented into rectum, small intestine, appendix, and others. Lung segment is sub-segmented into typical, atypical, and others.

On the basis of the diagnosis, the [FURL=https://www.marketresearchfuture.com/reports/carcinoid-tumor-market-4813]Carcinoid Tumor Market[/FURL] is segmented into serology, imaging, biopsy, and others. The serology segment is sub-segmented into blood test, urine test, molecular test, and others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and others.

On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiotherapy, and others. The surgery segment is sub-segmented into local excision, radiofrequency ablation (RFA), and others.

On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.

Carcinoid Tumor Market Key Players

Some of the key players in the global carcinoid tumor market are Novartis AG (Europe), Amgen Inc. (U.S.), Boehringer Ingelheim GmbH (Europe), AVEO Pharmaceuticals, Inc. (U.S.), Chiasma, Inc. (U.S.), Aegis Therapeutics, LLC (U.S.), CRINETICS PHARMACEUTICALS (U.S.), Delcath Systems Inc. (U.S.), Exelixis, Inc. (U.S.), and others.

For more details [FURL=https://www.marketresearchfuture.com/reports/carcinoid-tumor-market-4813]Click Here[/FURL]

 

Plans | FAQs | Contact Us | Terms & Conditions | Privacy Policy